NCT04843774View on ClinicalTrials.gov

Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)

CompletedOBSERVATIONAL
Enrollment

64

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

April 18, 2023

Study Completion Date

April 18, 2023

Conditions
Multiple Sclerosis
Interventions
DRUG

SARS-COV-2 mRNA Vaccine

Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus will be given as standard of care (SOC)

Trial Locations (2)

10016

NYU Langone Health Multiple Sclerosis Comprehensive Care Center (NYULH MSCCC), New York

80204

University of Colorado, Denver (UCD), Denver

All Listed Sponsors
lead

NYU Langone Health

OTHER